Armata Pharmaceuticals Inc. (NYSE American: ARMP) announced it will delay reporting its fourth quarter and full-year 2025 financial results, requiring additional time to complete its financial reporting. The company anticipates filing its Annual Report on Form 10-K by March 31, 2026.

The FDA granted Armata's AP-SA02 product candidate Qualified Infectious Disease Product designation for treating complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive or methicillin-resistant strains. The QIDP designation provides eligibility for certain development incentives under the GAIN Act, including an additional five-year extension of market exclusivity.

Following an End-of-Phase 2 meeting, the FDA confirmed that safety and efficacy data from Armata's Phase 2a diSArm study are sufficient to initiate a Phase 3 trial. The agency provided guidance on the Phase 3 study design, which will assess AP-SA02's superiority over current standard care for complicated bacteremia treatment. The Phase 3 study is expected to begin in the second half of 2026.

The company formally commissioned its 56,000 square foot manufacturing facility in Los Angeles, California, which includes 10,000 square feet of current Good Manufacturing Practice clean rooms and an automated fill and finish suite. The facility has completed full production runs.

Results from the Phase 2a diSArm study were presented at IDWeek 2025, showing that AP-SA02 combined with antibiotic therapy had higher cure rates compared to placebo at day 12. Patients receiving AP-SA02 demonstrated a 100% response rate without relapse one week post-treatment and 28 days later, compared to approximately 25% lack of response or relapse in the placebo group.

"The major highlight since our last quarterly update was the End-of-Phase 2 meeting with the FDA, which enabled us to reach alignment with the Agency on a plan forward for AP-SA02," stated Chief Executive Officer Deborah Birx.